nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—thyroid cancer	0.951	1	CbGaD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00756	0.17	CbGpPWpGaD
Tafluprost—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00604	0.136	CbGpPWpGaD
Tafluprost—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00454	0.102	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00271	0.0608	CbGpPWpGaD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00247	0.0554	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00164	0.0368	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.0016	0.036	CbGpPWpGaD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00136	0.0305	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CALCB—thyroid cancer	0.00109	0.0246	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000665	0.0149	CbGpPWpGaD
Tafluprost—Visual acuity reduced—Vandetanib—thyroid cancer	0.00063	0.136	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—CALCB—thyroid cancer	0.000619	0.0139	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000609	0.0137	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CALCB—thyroid cancer	0.000562	0.0126	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000518	0.0116	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—TSHR—thyroid cancer	0.000507	0.0114	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.00047	0.0106	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTCH1—thyroid cancer	0.000431	0.00968	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—SST—thyroid cancer	0.000394	0.00885	CbGpPWpGaD
Tafluprost—Cataract—Vandetanib—thyroid cancer	0.000394	0.0851	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CALCA—thyroid cancer	0.000379	0.00852	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000374	0.0084	CbGpPWpGaD
Tafluprost—Dry eye—Vandetanib—thyroid cancer	0.000346	0.0748	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—CALCB—thyroid cancer	0.000332	0.00745	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000321	0.00721	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TRIM33—thyroid cancer	0.000315	0.00707	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—TSHR—thyroid cancer	0.000286	0.00643	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—TSHR—thyroid cancer	0.00026	0.00584	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000256	0.00575	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000245	0.0055	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Vandetanib—thyroid cancer	0.000243	0.0526	CcSEcCtD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000234	0.00527	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000233	0.00523	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—SST—thyroid cancer	0.000223	0.005	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTCH1—thyroid cancer	0.000221	0.00497	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000218	0.00491	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CALCA—thyroid cancer	0.000214	0.00482	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000211	0.00473	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TCF7L1—thyroid cancer	0.00021	0.00472	CbGpPWpGaD
Tafluprost—Urinary tract infection—Vandetanib—thyroid cancer	0.000204	0.0441	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000203	0.00456	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SST—thyroid cancer	0.000202	0.00454	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CALCA—thyroid cancer	0.000195	0.00437	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000188	0.00422	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000179	0.00402	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CDK1—thyroid cancer	0.000176	0.00396	CbGpPWpGaD
Tafluprost—Eye disorder—Vandetanib—thyroid cancer	0.000176	0.038	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000176	0.00394	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TRIM24—thyroid cancer	0.000164	0.00369	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Sorafenib—thyroid cancer	0.000164	0.0355	CcSEcCtD
Tafluprost—PTGS2—Metabolism—MINPP1—thyroid cancer	0.000162	0.00364	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00016	0.00359	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CHST14—thyroid cancer	0.000155	0.00347	CbGpPWpGaD
Tafluprost—Vision blurred—Vandetanib—thyroid cancer	0.000154	0.0334	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—TSHR—thyroid cancer	0.000154	0.00345	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000151	0.0034	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000151	0.0034	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TRIM33—thyroid cancer	0.000147	0.00329	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MEN1—thyroid cancer	0.000144	0.00324	CbGpPWpGaD
Tafluprost—Cough—Vandetanib—thyroid cancer	0.000143	0.0309	CcSEcCtD
Tafluprost—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000138	0.00309	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000134	0.00301	CbGpPWpGaD
Tafluprost—Nervous system disorder—Vandetanib—thyroid cancer	0.000131	0.0283	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—PTCH1—thyroid cancer	0.000131	0.00293	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	0.00013	0.00292	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CHST14—thyroid cancer	0.000129	0.00291	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SST—thyroid cancer	0.000119	0.00268	CbGpPWpGaD
Tafluprost—Dyspnoea—Vandetanib—thyroid cancer	0.000119	0.0258	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—CALCA—thyroid cancer	0.000115	0.00258	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	0.000111	0.00248	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HPGD—thyroid cancer	0.000104	0.00235	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CDK1—thyroid cancer	0.000104	0.00234	CbGpPWpGaD
Tafluprost—Lacrimation increased—Epirubicin—thyroid cancer	0.000101	0.0219	CcSEcCtD
Tafluprost—PTGS2—Disease—TCF7L1—thyroid cancer	9.78e-05	0.0022	CbGpPWpGaD
Tafluprost—Cough—Sorafenib—thyroid cancer	9.64e-05	0.0208	CcSEcCtD
Tafluprost—Pruritus—Vandetanib—thyroid cancer	9.46e-05	0.0205	CcSEcCtD
Tafluprost—Lacrimation increased—Doxorubicin—thyroid cancer	9.38e-05	0.0203	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.1e-05	0.00204	CbGpPWpGaD
Tafluprost—Nervous system disorder—Sorafenib—thyroid cancer	8.84e-05	0.0191	CcSEcCtD
Tafluprost—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	8.81e-05	0.00198	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.78e-05	0.00197	CbGpPWpGaD
Tafluprost—Dry eye—Epirubicin—thyroid cancer	8.63e-05	0.0187	CcSEcCtD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.47e-05	0.0019	CbGpPWpGaD
Tafluprost—Headache—Vandetanib—thyroid cancer	8.37e-05	0.0181	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—NRG1—thyroid cancer	8.36e-05	0.00188	CbGpPWpGaD
Tafluprost—Dyspnoea—Sorafenib—thyroid cancer	8.04e-05	0.0174	CcSEcCtD
Tafluprost—Dry eye—Doxorubicin—thyroid cancer	7.98e-05	0.0173	CcSEcCtD
Tafluprost—Eye pain—Epirubicin—thyroid cancer	7.51e-05	0.0162	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—TERT—thyroid cancer	7.5e-05	0.00169	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HIF1A—thyroid cancer	7.17e-05	0.00161	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TPR—thyroid cancer	7.16e-05	0.00161	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PRKAR1A—thyroid cancer	7.04e-05	0.00158	CbGpPWpGaD
Tafluprost—Eye pain—Doxorubicin—thyroid cancer	6.95e-05	0.015	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.74e-05	0.00152	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MEN1—thyroid cancer	6.73e-05	0.00151	CbGpPWpGaD
Tafluprost—Pruritus—Sorafenib—thyroid cancer	6.38e-05	0.0138	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—NRAS—thyroid cancer	6.32e-05	0.00142	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Epirubicin—thyroid cancer	6.06e-05	0.0131	CcSEcCtD
Tafluprost—PTGS2—Metabolism—TPR—thyroid cancer	6e-05	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.99e-05	0.00135	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—BRAF—thyroid cancer	5.94e-05	0.00133	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PRKAR1A—thyroid cancer	5.9e-05	0.00133	CbGpPWpGaD
Tafluprost—Asthma—Epirubicin—thyroid cancer	5.86e-05	0.0127	CcSEcCtD
Tafluprost—Headache—Sorafenib—thyroid cancer	5.65e-05	0.0122	CcSEcCtD
Tafluprost—Nasopharyngitis—Doxorubicin—thyroid cancer	5.61e-05	0.0121	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—KRAS—thyroid cancer	5.44e-05	0.00122	CbGpPWpGaD
Tafluprost—Asthma—Doxorubicin—thyroid cancer	5.42e-05	0.0117	CcSEcCtD
Tafluprost—PTGS2—Disease—CALCA—thyroid cancer	5.36e-05	0.0012	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.35e-05	0.0012	CbGpPWpGaD
Tafluprost—Urinary tract infection—Epirubicin—thyroid cancer	5.08e-05	0.011	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.06e-05	0.00114	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CDK1—thyroid cancer	4.85e-05	0.00109	CbGpPWpGaD
Tafluprost—Rhinitis—Epirubicin—thyroid cancer	4.7e-05	0.0102	CcSEcCtD
Tafluprost—Urinary tract infection—Doxorubicin—thyroid cancer	4.7e-05	0.0102	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—HRAS—thyroid cancer	4.62e-05	0.00104	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKT1—thyroid cancer	4.5e-05	0.00101	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC5A5—thyroid cancer	4.49e-05	0.00101	CbGpPWpGaD
Tafluprost—Eye disorder—Epirubicin—thyroid cancer	4.38e-05	0.00948	CcSEcCtD
Tafluprost—Rhinitis—Doxorubicin—thyroid cancer	4.35e-05	0.00941	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—CCND1—thyroid cancer	4.34e-05	0.000974	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTEN—thyroid cancer	4.19e-05	0.00094	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKT1—thyroid cancer	4.08e-05	0.000917	CbGpPWpGaD
Tafluprost—Eye disorder—Doxorubicin—thyroid cancer	4.06e-05	0.00877	CcSEcCtD
Tafluprost—PTGS2—Disease—NRG1—thyroid cancer	3.89e-05	0.000875	CbGpPWpGaD
Tafluprost—Vision blurred—Epirubicin—thyroid cancer	3.85e-05	0.00832	CcSEcCtD
Tafluprost—PTGS2—Metabolism—RXRA—thyroid cancer	3.77e-05	0.000847	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRAS—thyroid cancer	3.73e-05	0.000839	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.67e-05	0.000824	CbGpPWpGaD
Tafluprost—Cough—Epirubicin—thyroid cancer	3.56e-05	0.00771	CcSEcCtD
Tafluprost—Vision blurred—Doxorubicin—thyroid cancer	3.56e-05	0.0077	CcSEcCtD
Tafluprost—PTGS2—Disease—TERT—thyroid cancer	3.5e-05	0.000785	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIF1A—thyroid cancer	3.34e-05	0.000751	CbGpPWpGaD
Tafluprost—Cough—Doxorubicin—thyroid cancer	3.3e-05	0.00713	CcSEcCtD
Tafluprost—Nervous system disorder—Epirubicin—thyroid cancer	3.27e-05	0.00707	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—KRAS—thyroid cancer	3.21e-05	0.000722	CbGpPWpGaD
Tafluprost—Nervous system disorder—Doxorubicin—thyroid cancer	3.02e-05	0.00654	CcSEcCtD
Tafluprost—Dyspnoea—Epirubicin—thyroid cancer	2.97e-05	0.00642	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—TP53—thyroid cancer	2.86e-05	0.000642	CbGpPWpGaD
Tafluprost—PTGS2—Disease—BRAF—thyroid cancer	2.77e-05	0.000622	CbGpPWpGaD
Tafluprost—Dyspnoea—Doxorubicin—thyroid cancer	2.75e-05	0.00594	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—HRAS—thyroid cancer	2.73e-05	0.000614	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT1—thyroid cancer	2.41e-05	0.000542	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARG—thyroid cancer	2.38e-05	0.000535	CbGpPWpGaD
Tafluprost—Pruritus—Epirubicin—thyroid cancer	2.36e-05	0.0051	CcSEcCtD
Tafluprost—Pruritus—Doxorubicin—thyroid cancer	2.18e-05	0.00472	CcSEcCtD
Tafluprost—Headache—Epirubicin—thyroid cancer	2.09e-05	0.00451	CcSEcCtD
Tafluprost—PTGS2—Disease—PTEN—thyroid cancer	1.95e-05	0.000438	CbGpPWpGaD
Tafluprost—Headache—Doxorubicin—thyroid cancer	1.93e-05	0.00418	CcSEcCtD
Tafluprost—PTGS2—Disease—NRAS—thyroid cancer	1.74e-05	0.000391	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTEN—thyroid cancer	1.63e-05	0.000367	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KRAS—thyroid cancer	1.5e-05	0.000336	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HRAS—thyroid cancer	1.27e-05	0.000286	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT1—thyroid cancer	1.12e-05	0.000253	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKT1—thyroid cancer	9.41e-06	0.000211	CbGpPWpGaD
